Evidence map›Paper›PMID 42656953›Full record

ReviewiMeta2026

Multi-omics-driven precision medicine.

Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu and 11 more

Abstract readReview
In one paragraph

Review in iMeta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Huibo LiSchool of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology Macau SAR China.ORCID https://orcid.org/0000-0001-6807-8099
Zhe ZhaoDepartment of Pharmacy Peking University Third Hospital; Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center; Institute for Drug Evaluation, Peking University Health Science Center Beijing China.
Yifan ZhangSchool of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology Macau SAR China.
Yao MaDepartment of General Surgery Cancer Center, Peking University Third Hospital Beijing China.
Gaofei HuThe Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University Beijing China.
Min ZengDepartment of Immunology School of Basic Medical Sciences, NHC Key Laboratory of Medical Immunology, Medicine Innovation Center for Fundamental Researches on Major Immunology-Related Diseases, Peking University Beijing China.
Zhanqun YangDepartment of Pharmacy Peking University Third Hospital; Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center; Institute for Drug Evaluation, Peking University Health Science Center Beijing China.
Zixuan ZhaoMinistry of Education Key Laboratory of Bioinformatics, Bioinformatics Division at the Beijing National Research Center for Information Science and Technology, Center for Synthetic and Systems Biology, Department of Automation Tsinghua University Beijing China.
Xin ZhouDepartment of General Surgery Cancer Center, Peking University Third Hospital Beijing China.
Wei HuSchool of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology Macau SAR China.
Yuxuan SunDepartment of Pharmacy Peking University Third Hospital; Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center; Institute for Drug Evaluation, Peking University Health Science Center Beijing China.
Meng SuCollege of Pharmacy, University of Louisiana at Monroe Monroe Louisiana USA.
Jun LiDepartment of Gastroenterology Peking University Third Hospital Beijing China.
Matthew WhitemanUniversity of Exeter Medical School Exeter UK.
Wei FuDepartment of General Surgery Cancer Center, Peking University Third Hospital Beijing China.
Chao ZhongDepartment of Immunology School of Basic Medical Sciences, NHC Key Laboratory of Medical Immunology, Medicine Innovation Center for Fundamental Researches on Major Immunology-Related Diseases, Peking University Beijing China.
Lemin ZhengThe Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University Beijing China.ORCID https://orcid.org/0000-0003-4473-6936
Long ChenDepartment of Pharmacy Peking University Third Hospital; Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center; Institute for Drug Evaluation, Peking University Health Science Center Beijing China.
Hairong LvMinistry of Education Key Laboratory of Bioinformatics, Bioinformatics Division at the Beijing National Research Center for Information Science and Technology, Center for Synthetic and Systems Biology, Department of Automation Tsinghua University Beijing China.
Rongsheng ZhaoSchool of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology Macau SAR China.
Yi Zhun ZhuSchool of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology Macau SAR China.ORCID https://orcid.org/0000-0001-7700-8041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine is increasingly constrained not by a lack of molecular data but by the absence of frameworks that can translate multidimensional biological information into actionable clinical decisions. Multi-omics-driven precision medicine (MODPM) addresses this lack by integrating genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome, and clinical context into a multiscale framework that links molecular mechanisms, tissue organization, and patient trajectories. In this review, we propose a conceptual framework for MODPM and examine how advances in multi-omics technologies, artificial intelligence (AI), and foundation models are reshaping disease modeling, drug development, and precision intervention. We summarize the biological contributions of major omics layers and discuss how AI supports cross-modal representation learning, contextual modeling, and perturbation-aware prediction. We highlight drug development as a key translational application of MODPM and further discuss its clinical relevance across three major disease contexts: cancer, autoimmune diseases, and metabolic disorders, including cardiometabolic and renal-metabolic diseases. These examples illustrate how MODPM can support target discovery, disease endotyping, treatment response prediction, and clinical monitoring by analyzing shared mechanisms such as immune dysregulation, metabolic remodeling, chronic inflammation, tissue microenvironmental changes, and gene-environment interactions. Across these settings, MODPM enables finer molecular stratification, the identification of pathway-dominant disease states, improved response prediction, and dynamic treatment monitoring. We also discuss key barriers to implementation, including data heterogeneity, limited cohort diversity, polygenic complexity, workflow constraints, cost, and ethical issues related to privacy, consent, and data ownership. Overall, the value of MODPM lies not in stacking additional data layers but in building a multiscale, continuously learnable framework to link biological heterogeneity to clinically interpretable and actionable decisions.

Indexed as

artificial intelligenceclinical decision‐makingmulti‐omicsprecision medicinetranslational medicine

Identifiers

PMID42656953
PMCPMC13507694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.